Co-Authors
This is a "connection" page, showing publications co-authored by WILLIAM H MORRISON and RENATA FERRAROTTO.
Connection Strength
1.697
-
Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Apr 14; 28(8):1735.
Score: 0.214
-
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565.
Score: 0.203
-
Unilateral Radiation Therapy for Tonsillar Cancer: Treatment Outcomes in the Era of Human Papillomavirus, Positron-Emission Tomography, and Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022 08 01; 113(5):1054-1062.
Score: 0.054
-
Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, single-institution, modern cohort study. Head Neck. 2021 11; 43(11):3331-3344.
Score: 0.051
-
Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience. Int J Part Ther. 2021; 8(1):108-118.
Score: 0.051
-
Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer. Int J Part Ther. 2021; 8(1):213-222.
Score: 0.051
-
Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life. Int J Part Ther. 2021; 8(1):234-247.
Score: 0.051
-
Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy. Curr Treat Options Oncol. 2021 06 04; 22(6):54.
Score: 0.050
-
Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation. Oral Oncol. 2021 02; 113:105125.
Score: 0.049
-
Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. Cancer. 2021 04 15; 127(8):1228-1237.
Score: 0.049
-
Highly conformal reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes. Head Neck. 2020 11; 42(11):3326-3335.
Score: 0.048
-
The impact of tongue-deviating and tongue-depressing oral stents on long-term radiation-associated symptoms in oropharyngeal cancer survivors. Clin Transl Radiat Oncol. 2020 Sep; 24:71-78.
Score: 0.047
-
Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage. Adv Radiat Oncol. 2020 Sep-Oct; 5(5):929-935.
Score: 0.047
-
Patient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy. Radiother Oncol. 2020 07; 148:258-266.
Score: 0.047
-
Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer. Radiother Oncol. 2020 07; 148:133-139.
Score: 0.047
-
Neurologic sequelae following radiation with and without chemotherapy for oropharyngeal cancer: Patient reported outcomes study. Head Neck. 2020 08; 42(8):2137-2144.
Score: 0.046
-
Prospective observational evaluation of radiation-induced late taste impairment kinetics in oropharyngeal cancer patients: Potential for improvement over time? Clin Transl Radiat Oncol. 2020 May; 22:98-105.
Score: 0.046
-
A prospective evaluation of health-related quality of life after skull base re-irradiation. Head Neck. 2020 03; 42(3):485-497.
Score: 0.046
-
Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. NPJ Precis Oncol. 2019; 3:22.
Score: 0.045
-
Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. Radiother Oncol. 2020 01; 142:133-139.
Score: 0.045
-
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2019 08; 29(8):1036-1043.
Score: 0.044
-
Patient Outcomes after Reirradiation of Small Skull Base Tumors using Stereotactic Body Radiotherapy, Intensity Modulated Radiotherapy, or Proton Therapy. J Neurol Surg B Skull Base. 2020 Dec; 81(6):638-644.
Score: 0.044
-
Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. Cancer. 2019 06 01; 125(11):1823-1829.
Score: 0.043
-
Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling. BMC Cancer. 2018 Sep 19; 18(1):903.
Score: 0.042
-
Age-adjusted comorbidity and survival in locally advanced laryngeal cancer. Head Neck. 2018 09; 40(9):2060-2069.
Score: 0.041
-
Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. Oral Oncol. 2018 04; 79:1-8.
Score: 0.040
-
Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy. Cancer. 2018 04 01; 124(7):1415-1427.
Score: 0.040
-
Correction to: Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients =65?years old. Radiat Oncol. 2017 11 23; 12(1):186.
Score: 0.040
-
Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients =65?years old. Radiat Oncol. 2017 Sep 09; 12(1):150.
Score: 0.039
-
Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. Head Neck. 2017 08; 39(8):1609-1620.
Score: 0.038